Key facts
- Valora Therapeutics’s last known valuation is $38.7M (Nov 2024).
- It has raised $30.0M across 1 recorded rounds; the latest was Early Stage VC ($13.0M) in Jul 2024.
- Notable investors include Correlation Ventures, Alexandria Venture Investments, Standish Spring Investments, 28 Capital, Avalon Bioventures — 8 tracked in total.
- Valora Therapeutics has filed 1 Form D with the SEC, most recently Jul 2024 ($13.0M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Valora Therapeutics
Funding rounds
1 roundsAbout Valora Therapeutics
Operator of a pre-clinical stage biopharmaceutical company based in San Diego, California. The company specializes in the development of a new biological drug that enables the engineering of chimeric antibodies to unlock new mechanisms of immune signaling and activity, providing healthcare industry with transformative therapies in oncology and immune diseases.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2023
- Employees
- 6
- Website
- valoratherapeutics.com/
- Ownership
- Privately Held (backing)
Valora Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Valora Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Valora Therapeutics in its N-PORT filings yet. We sweep new filings monthly.